Brief Summary

Video assisted thoracoscopic surgery (VATS) is a minimally invasive surgery to remove lesions from the thoracic cavity. It is associated with moderate pain which can lead to pulmonary complications after surgery. The Enhanced Recovery After Surgery (ERAS) and the European Society of Thoracic Surgeons recommended a multimodal analgesia approach to manage pain after VATS. Erector spinae block (ESB) is a popular analgesic block due to its ease of performance and wide coverage. It has been shown to be effective in randomized control trials. Recently, case reports on bi-level ESB are emerging, suggesting more effective analgesia compared to single level ESB. As there is no available data, the investigators are interested in conducting a randomized pilot study, comparing bi-level to single level ESB to gather baseline data for sample size calculation for a formal randomized trial.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 24, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2022

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2023

Completed
Last Updated

March 24, 2022

Status Verified

March 1, 2022

Enrollment Period

7 months

First QC Date

January 11, 2022

Last Update Submit

March 15, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Opioid use in first 12 postoperaive hour

    First 12 hour from arriving at postoperative recovery

Secondary Outcomes (4)

  • Pain score area under curve first 12 hour

    First 12 hour from arriving at postoperative recovery

  • Pain score area under curve first 24 hour

    First 24 hour from arriving at postoperative recovery

  • Incidence of Acute block complication - based on clinical assessment

    First 12 hour since block placement

  • Incidence of Delayed block complication - based on clinical assessment

    First 5 days

Study Arms (2)

Single level block arm - Control

ACTIVE COMPARATOR

Single level erector spinae block at 4th transverse process

Procedure: Single level erector spinae block

Bi-level block arm - Intervention

EXPERIMENTAL

Bi-level erector spinae block at 4th and 6th transverse process

Procedure: Bi-level erector spinae block

Interventions

erector spinae block at 4th and 6th transverse process

Bi-level block arm - Intervention

erector spinae block at 4th transverse process

Single level block arm - Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult patients (at least 18 years old)
  • elective unilateral wedge resection, segmentectomy, lobectomy or bilobectomy via VATS

You may not qualify if:

  • history of malignant hyperthermia
  • BMI \> 40, chronic pain condition
  • Daily opioid consumption of more than 60 mg oral morphine equivalents
  • Conversion to thoracotomy
  • Insertion of epidural
  • postoperative admission to ICU

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cheng Lin

London, Ontario, n6c6a7, Canada

Location

MeSH Terms

Conditions

Acute Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

January 11, 2022

First Posted

March 24, 2022

Study Start

June 1, 2022

Primary Completion

January 1, 2023

Study Completion

February 1, 2023

Last Updated

March 24, 2022

Record last verified: 2022-03

Locations